Lingbo Biotechnology (Hangzhou)

Lingbo Biotechnology (Hangzhou) Co., Ltd. is a biotechnology firm established in 2019, specializing in the field of tissue-engineered medical devices. The company is focused on the research and development of biologic artificial blood vessels. Its main product under development is the "Skeletal Acellular Vessels" (SAV), a biological artificial blood vessel that is positioned to be a pioneering product of its kind in the Chinese market.

The company was founded by Kong Deling, a professor and doctoral supervisor at the College of Life Sciences at Nankai University. Kong is a recipient of the National Science Fund for Distinguished Young Scholars and leads an innovation team recognized by the Ministry of Education.

Lingbo Biotechnology operates in the medical device sector, specifically targeting the market for artificial organs and organ protection products. The company's business model revolves around the research, development, clinical trials, and eventual production and commercialization of its proprietary medical devices. Since its inception, the company has successfully completed several funding rounds, including a Series A+ round in June 2024 led by Tasly Holding Group, a Series A round in November 2023, a Pre-A round in April 2021, and an angel round in August 2020. These funds are allocated to advance clinical trials for existing products and to support the research and development of new applications, such as artificial blood vessels for cardiac bypass surgery.

Keywords: biologic artificial blood vessels, tissue engineering, medical devices, skeletal acellular vessels, SAV, regenerative medicine, organ protection, peripheral vascular disease, cardiac bypass surgery, polymer de-purification technology